Table 5.
Naloxone Study |
Naloxone methiodide Study |
|||
---|---|---|---|---|
Parameter | Vehicle | NLX | Vehicle | NLXmi |
Frequency (breaths/min) x min | −582 ± 69* | 246 ± 38*,† | −435 ± 51* | −502 ± 60* |
Tidal Volume (mls) x min | 2.14 ± 0.56 | −0.13 ± 0.18 | 4.06 ± 0.52* | 5.04 ± 0.58* |
Minute Ventilation (mls/min) x min | −679 ± 73* | 455 ± 67*,† | −444 ± 53* | −337 ± 46* |
Inspiratory Time (sec) x min | 2.27 ± 0.36* | −0.25 ± 0.08† | 2.25 ± 0.37* | 1.80 ± 0.29* |
Expiratory Time (sec) x min | 0.13 ± 0.06 | −0.16 ± 0.08 | −0.15 ± 0.06 | −0.20 ± 0.07 |
End Inspiratory Pause (msec) x min | 121 ± 17* | −9 ± 6 | 109 ± 15* | 66 ± 9*,† |
Peak Inspiratory Flow (mls/sec) x min | −141 ± 13* | 20 ± 3*,† | −91 ± 9* | −78 ± 9* |
Peak Expiratory Flow (mls/sec) x min | 24 ± 3* | 1 ± 6*,† | 28 ± 4* | 18 ± 4* |
Data are presented as mean ± SEM. NLX, naloxone. NLXmi, Naloxone methiodide. There were 6 rats in each group. P < 0.05, significant Response Area.
P < 0.05, NLX or NLXmi versus relevant vehicle.